# US 2014/0194372 A1 · Heart failure suppressing agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194372 A1
- Document ID: US20140194372A1
- Status: Published application
- Kind: A1
- Application number: 14/233,581
- Filed: 2012-07-19
- Published: 2014-07-10
- Earliest claimed: 2011-07-20
- Assignees: Theravalues Corporation; The University of Tokyo
- Inventors: Hiroyuki Morita; Ryozo Nagai; Atsuko Nakayama; Tadashi Hashimoto
- Web page: https://patentgrep.com/patent/US20140194372A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C07D 311/30: not hydrogenated in the hetero ring, e.g. flavones
- C07H 17/07: Benzo[b]pyran-4-ones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method of suppressing at least one heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, the method comprising administering an effective amount of luteolin or a derivative thereof to a subject in need thereof.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the luteolin or a derivative thereof is a compound of formula (1):
wherein R1, R2, R3 and R4 are each independently, a hydrogen atom, an alkyl group, a sulfo group or a sugar residue.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the luteolin or a derivative thereof is luteolin or luteolin-7-O-glucoside.

### Claim 22

A method of suppressing aneurysm, comprising administering an effective amount of luteolin or a derivative thereof to a subject in need thereof.

### Claim 23 (depends on 22)

The method according to claim 22, wherein the luteolin or a derivative thereof is a compound of formula (1):
wherein R1, R2, R3 and R4 are each independently, a hydrogen atom, an alkyl group, a sulfo group or a sugar residue.

### Claim 24 (depends on 22)

The method according to claim 22, wherein the luteolin or a derivative thereof is luteolin or luteolin-7-O-glucoside.

### Claim at position 8

25-26. (canceled)

### Claim 27 (depends on 20)

The method according to claim 20, wherein the luteolin or a derivative thereof is luteolin or luteolin-7-O-glucoside.

### Claim 28 (depends on 23)

The method according to claim 23, wherein the luteolin or a derivative thereof is luteolin or luteolin-7-O-glucoside.